{
    "organizations": [],
    "uuid": "e59f9e11b0341271046dc9063ff8a832dc93d7b8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kala-pharmaceuticals-reports-q1-lo/brief-kala-pharmaceuticals-reports-q1-loss-per-share-of-0-46-idUSASC0A1CA",
    "ord_in_thread": 0,
    "title": "BRIEF-Kala Pharmaceuticals Reports Q1 Loss Per Share Of $0.46",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - Kala Pharmaceuticals Inc:\n* KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.46 * Q1 EARNINGS PER SHARE VIEW $-0.45 â€” THOMSON REUTERS I/B/E/S\n* AS OF MARCH 31, 2018, HAD CASH OF $100.5 MILLION COMPARED TO $114.6 MILLION AS OF DECEMBER 31, 2017\n* ANTICIPATES THAT ITS EXISTING CASH ON HAND WILL ENABLE IT TO FUND OPERATIONS THROUGH AT LEAST NEXT TWELVE MONTHS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T19:13:00.000+03:00",
    "crawled": "2018-05-11T12:54:25.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "kala",
        "pharmaceutical",
        "inc",
        "kala",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "march",
        "cash",
        "million",
        "compared",
        "million",
        "december",
        "anticipates",
        "existing",
        "cash",
        "hand",
        "enable",
        "fund",
        "operation",
        "least",
        "next",
        "twelve",
        "month",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}